Clinical trials: Cat Allergy
Asthma
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction…
- Trial name
- AERO (NCT00495612)
- Testing
- Omalizumab
- Volunteers
- 69 people
- Sponsor
- Genentech, Inc.
Cat Allergy
The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, cells in the blood and cells in the…
- Trial name
- NCT01003301
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Cat Allergy
Phase III Cat-PAD Follow-on Study
The purpose of this study is to evaluate the continued effectiveness and safety of Cat-PAD in cat allergic subjects for up to five years after the start of administration of treatment.
- Trial name
- NCT02040844
- Testing
- Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762], Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762], Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]
- Volunteers
- 430 people
- Sponsor
- Circassia Limited
Allergic Rhinitis
The Effect of Omalizumab on Responses to Cat Allergen Challenge
This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, skin and blood that cause allergies.
- Trial name
- NCT00604786
- Testing
- omalizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Rhinoconjunctivitis
Paediatric Safety Study in Cat-PAD
Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects
- Trial name
- NCT01921257
- Testing
- Cat-PAD
- Where
- 3 sites in Poland
- Volunteers
- 16 people
- Sponsor
- Circassia Limited
Allergic Rhinitis Due to Cat Allergy
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.
- Trial name
- NCT04981717
- Testing
- REGN1908-1909
- Where
- 92 sites in United States, Belgium and 4 more
- Volunteers
- 446 people
- Sponsor
- Regeneron Pharmaceuticals
Cat Allergy
Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy
The purpose of this trial is to show that Intradermal Human Fcγ1-Fel d1 fusion protein (GFD) is able to block the skin reaction to cat allergen in cat allergic subjects compared to the skin reaction to cat allergen alone.
- Trial name
- NCT01292070
- Testing
- Intradermal Human Fcγ1-Fel d1 fusion protein, Positive Control - standardized cat hair allergenic extract (CAT), Positive Control - Histamine Prick
- Where
- Australia
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma, Atopy
Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma is a disease of rapidly increasing incidence that already affects more than 17 million people in the United States alone.
- Trial name
- NCT01547286
- Testing
- Standardized Cat Allergen Extract and Standardized Dust Mite Allergen, Computed Tomography imaging, functional Positron Emission Tomography imaging, Nebulized methacholine inhalation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Rhinoconjunctivitis
Phase II HDM-SPIRE Safety and Efficacy Study
The purpose of this study is to compare the treatment effect of three treatment regimens of HDM-SPIRE vs placebo and to evaluates the treatment effect of HDM-SPIRE on symptoms, rescue medication usage, Quality of Life and Sleep…
- Trial name
- NCT02150343
- Testing
- HDM-SPIRE
- Where
- 98 sites in United States, Canada and 6 more
- Volunteers
- 715 people
- Sponsor
- Circassia Limited
Cat Allergy, Mild Asthma
Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge
The primary objective is to evaluate the prophylactic efficacy of REGN1908-1909 (anti-Fel d 1) administered as a single dose on day 1 in cat-allergic asthmatic patients not living with a cat in the prevention of a Controlled Cat…
- Trial name
- NCT03838731
- Testing
- REGN1908-1909
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Conjunctivitis
Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.
- Trial name
- NCT00534794
- Testing
- Elestat, Pataday
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Merck Sharp & Dohme LLC
Allergy
Phase 2 Study in Adults Sensitized to Cat
The purpose of this study is to identify an effective dose of allergen-specific immunotherapy for cat hair (Felis domesticus) administered by the oral/sublingual route.
- Trial name
- NCT00689299
- Testing
- Standardized Allergenic Extract, Cat Hair
- Where
- 3 sites in United States
- Volunteers
- 167 people
- Sponsor
- Antigen Laboratories, Inc.
Rhinoconjunctivitis
Phase III Cat-PAD Study
The purpose of this study is to compare the treatment effect of two treatment regimens of Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue medication usage and Quality of Life.
- Trial name
- NCT01620762
- Testing
- Cat-PAD
- Where
- 118 sites in United States, Belgium and 7 more
- Volunteers
- 1,408 people
- Sponsor
- Circassia Limited
Cat Allergy, Cat Hypersensitivity
Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy
This trial will test whether a novel therapeutic approach, cat immunotherapy combined with an investigational new drug called MEDI9929/AMG 157 (an anti-TSLP [thymic stromal lymphopoietin] antibody being co-developed by Amgen and…
- Trial name
- NCT02237196
- Testing
- AMG 157, Cat Immunotherapy
- Where
- 9 sites in United States
- Volunteers
- 121 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)